Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
300158.SZ
SELLREMOVEShanxi Zhendong Pharmaceutical Co.,Ltd · Healthcare · China · $738M · Avg Vol: $10M/d
Shanxi Zhendong Pharmaceutical manufactures traditional Chinese medicines and generic pharmaceuticals. It operates in a highly regulated domestic market subject to government-mandated volume-based procurement price cuts, destroying its pricing power.
COMPANY DESCRIPTION
Shanxi Zhendong Pharmaceutical Co., Ltd. researches, manufactures, and markets traditional Chinese medicines (TCM), chemical generics, and oncology drugs. The company is a market leader in specialized therapeutic areas such as oncology supportive care and hair loss treatments. Its competitive moat is supported by a vertically integrated TCM supply chain, spanning raw herb cultivation to clinical distribution, and a robust domestic sales network.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|
| Revenue | 753M | 551M | 536M | 439M | -16.4% |
| EPS | 0.38 | -0.01 | -0.01 | -0.19 | — |
| Shares | 1.0B | 1.0B | 1.0B | 1.0B | -2.2% |
| Debt | 46M | 3M | 421,847 | 6M | -49.1% |
| Equity | 1.2B | 777M | 765M | 546M | -22.9% |
| Op CF | 42M | 13M | -37M | -22M | -69.7% |
| Inv CF | 52M | 354M | 70M | 6M | — |
| Fin CF | -57M | -440M | -21M | -14M | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 300158.SZ are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 300158.SZ | Shanxi Zhendong Pharmaceutical Co.,Ltd(you) | $738M | 34 | SELL |
| 002728.SZ | Teyi Pharmaceutical Group Co.,Ltd | $671M | 32 | SELL |
| 002793.SZ | Luoxin Pharmaceuticals Group Stock Co., Ltd. | $690M | 31 | SELL |
| 301277.SZ | Newland Pharmaceutical Co., Ltd. | $574M | 34 | SELL |
| 688247.SS | Sinotherapeutics Inc. | $571M | 33 | SELL |
| 002688.SZ | Jinhe Biotechnology CO., LTD. | $628M | 39 | HOLD |
| 300267.SZ | Hunan Er-Kang Pharmaceutical Co., Ltd | $1.1B | 34 | SELL |
| 688176.SS | Jiangsu Yahong Meditech Co., Ltd. | $961M | 30 | SELL |
| 002907.SZ | Chongqing Pharscin Pharmaceutical Co., Ltd. | $765M | 26 | SELL |
| 002038.SZ | Beijing SL Pharmaceutical Co., Ltd. | $893M | 28 | SELL |
Peer medians: ROE 4.8% · P/E 27.8x · Gross margin 53.1%